1146 related articles for article (PubMed ID: 30903796)
1. Effect of Additional Oral Semaglutide vs Sitagliptin on Glycated Hemoglobin in Adults With Type 2 Diabetes Uncontrolled With Metformin Alone or With Sulfonylurea: The PIONEER 3 Randomized Clinical Trial.
Rosenstock J; Allison D; Birkenfeld AL; Blicher TM; Deenadayalan S; Jacobsen JB; Serusclat P; Violante R; Watada H; Davies M;
JAMA; 2019 Apr; 321(15):1466-1480. PubMed ID: 30903796
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin, thiazolidinediones, or both, in patients with type 2 diabetes (SUSTAIN 2): a 56-week, double-blind, phase 3a, randomised trial.
Ahrén B; Masmiquel L; Kumar H; Sargin M; Karsbøl JD; Jacobsen SH; Chow F
Lancet Diabetes Endocrinol; 2017 May; 5(5):341-354. PubMed ID: 28385659
[TBL] [Abstract][Full Text] [Related]
3. Effect of Oral Semaglutide Compared With Placebo and Subcutaneous Semaglutide on Glycemic Control in Patients With Type 2 Diabetes: A Randomized Clinical Trial.
Davies M; Pieber TR; Hartoft-Nielsen ML; Hansen OKH; Jabbour S; Rosenstock J
JAMA; 2017 Oct; 318(15):1460-1470. PubMed ID: 29049653
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as add-on to metformin in patients with type 2 diabetes in SUSTAIN China: A 30-week, double-blind, phase 3a, randomized trial.
Ji L; Dong X; Li Y; Li Y; Lim S; Liu M; Ning Z; Rasmussen S; Skjøth TV; Yuan G; Eliaschewitz FG
Diabetes Obes Metab; 2021 Feb; 23(2):404-414. PubMed ID: 33074557
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of oral semaglutide with flexible dose adjustment versus sitagliptin in type 2 diabetes (PIONEER 7): a multicentre, open-label, randomised, phase 3a trial.
Pieber TR; Bode B; Mertens A; Cho YM; Christiansen E; Hertz CL; Wallenstein SOR; Buse JB;
Lancet Diabetes Endocrinol; 2019 Jul; 7(7):528-539. PubMed ID: 31189520
[TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of once-weekly semaglutide versus daily canagliflozin as add-on to metformin in patients with type 2 diabetes (SUSTAIN 8): a double-blind, phase 3b, randomised controlled trial.
Lingvay I; Catarig AM; Frias JP; Kumar H; Lausvig NL; le Roux CW; Thielke D; Viljoen A; McCrimmon RJ
Lancet Diabetes Endocrinol; 2019 Nov; 7(11):834-844. PubMed ID: 31540867
[TBL] [Abstract][Full Text] [Related]
7. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial.
Pratley R; Amod A; Hoff ST; Kadowaki T; Lingvay I; Nauck M; Pedersen KB; Saugstrup T; Meier JJ;
Lancet; 2019 Jul; 394(10192):39-50. PubMed ID: 31186120
[TBL] [Abstract][Full Text] [Related]
8. Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial.
Rodbard HW; Rosenstock J; Canani LH; Deerochanawong C; Gumprecht J; Lindberg SØ; Lingvay I; Søndergaard AL; Treppendahl MB; Montanya E;
Diabetes Care; 2019 Dec; 42(12):2272-2281. PubMed ID: 31530666
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of semaglutide once weekly vs sitagliptin once daily, both as monotherapy in Japanese people with type 2 diabetes.
Seino Y; Terauchi Y; Osonoi T; Yabe D; Abe N; Nishida T; Zacho J; Kaneko S
Diabetes Obes Metab; 2018 Feb; 20(2):378-388. PubMed ID: 28786547
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of once-weekly semaglutide versus once-daily insulin glargine as add-on to metformin (with or without sulfonylureas) in insulin-naive patients with type 2 diabetes (SUSTAIN 4): a randomised, open-label, parallel-group, multicentre, multinational, phase 3a trial.
Aroda VR; Bain SC; Cariou B; Piletič M; Rose L; Axelsen M; Rowe E; DeVries JH
Lancet Diabetes Endocrinol; 2017 May; 5(5):355-366. PubMed ID: 28344112
[TBL] [Abstract][Full Text] [Related]
11. Long-term efficacy and safety of oral semaglutide and the effect of switching from sitagliptin to oral semaglutide in patients with type 2 diabetes: a 52-week, randomized, open-label extension of the PIONEER 7 trial.
Buse JB; Bode BW; Mertens A; Cho YM; Christiansen E; Hertz CL; Nielsen MA; Pieber TR;
BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33318068
[TBL] [Abstract][Full Text] [Related]
12. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
[TBL] [Abstract][Full Text] [Related]
13. Canagliflozin provides greater attainment of both HbA1c and body weight reduction versus sitagliptin in patients with type 2 diabetes.
Schernthaner G; Lavalle-González FJ; Davidson JA; Jodon H; Vijapurkar U; Qiu R; Canovatchel W
Postgrad Med; 2016 Nov; 128(8):725-730. PubMed ID: 27391951
[TBL] [Abstract][Full Text] [Related]
14. Efficacy, Safety, and Tolerability of Oral Semaglutide Versus Placebo Added to Insulin With or Without Metformin in Patients With Type 2 Diabetes: The PIONEER 8 Trial.
Zinman B; Aroda VR; Buse JB; Cariou B; Harris SB; Hoff ST; Pedersen KB; Tarp-Johansen MJ; Araki E;
Diabetes Care; 2019 Dec; 42(12):2262-2271. PubMed ID: 31530667
[TBL] [Abstract][Full Text] [Related]
15. Efficacy and safety of dulaglutide versus sitagliptin after 52 weeks in type 2 diabetes in a randomized controlled trial (AWARD-5).
Nauck M; Weinstock RS; Umpierrez GE; Guerci B; Skrivanek Z; Milicevic Z
Diabetes Care; 2014 Aug; 37(8):2149-58. PubMed ID: 24742660
[TBL] [Abstract][Full Text] [Related]
16. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
Rubino DM; Greenway FL; Khalid U; O'Neil PM; Rosenstock J; Sørrig R; Wadden TA; Wizert A; Garvey WT;
JAMA; 2022 Jan; 327(2):138-150. PubMed ID: 35015037
[TBL] [Abstract][Full Text] [Related]
17. HARMONY 3: 104-week randomized, double-blind, placebo- and active-controlled trial assessing the efficacy and safety of albiglutide compared with placebo, sitagliptin, and glimepiride in patients with type 2 diabetes taking metformin.
Ahrén B; Johnson SL; Stewart M; Cirkel DT; Yang F; Perry C; Feinglos MN;
Diabetes Care; 2014 Aug; 37(8):2141-8. PubMed ID: 24898304
[TBL] [Abstract][Full Text] [Related]
18. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial.
Yamada Y; Katagiri H; Hamamoto Y; Deenadayalan S; Navarria A; Nishijima K; Seino Y;
Lancet Diabetes Endocrinol; 2020 May; 8(5):377-391. PubMed ID: 32333875
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of once-weekly semaglutide 2·0 mg versus 1·0 mg in patients with type 2 diabetes (SUSTAIN FORTE): a double-blind, randomised, phase 3B trial.
Frías JP; Auerbach P; Bajaj HS; Fukushima Y; Lingvay I; Macura S; Søndergaard AL; Tankova TI; Tentolouris N; Buse JB
Lancet Diabetes Endocrinol; 2021 Sep; 9(9):563-574. PubMed ID: 34293304
[TBL] [Abstract][Full Text] [Related]
20. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
Frías JP; Davies MJ; Rosenstock J; Pérez Manghi FC; Fernández Landó L; Bergman BK; Liu B; Cui X; Brown K;
N Engl J Med; 2021 Aug; 385(6):503-515. PubMed ID: 34170647
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
